1 / 31

PCI v CABG

PCI v CABG. Dr Rod Stables The Cardiothoracic Centre Liverpool UK. CABG is Alive and Well in Liverpool. CABG is Alive and Well in Liverpool. Liverpool Family Life. Liverpool Family Life. Presentation Outline. Undisputed current facts PCI improves access to revascularisation

leif
Download Presentation

PCI v CABG

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. PCI v CABG Dr Rod Stables The Cardiothoracic Centre Liverpool UK

  2. CABG is Alive and Well in Liverpool

  3. CABG is Alive and Well in Liverpool

  4. Liverpool Family Life

  5. Liverpool Family Life

  6. Presentation Outline • Undisputed current facts • PCI improves access to revascularisation • Availability

  7. Access to Revascularisation - Availability • Existing immediate capacity • Dominant method for revascularisation • UK PCI growth rate - 16% per annum • UK CABG growth rate - static or negative • Revascularisation event ratio trend > 2 : 1 • Immediate ability to grow capacity favours PCI • NSF targets - and beyond • New indications

  8. UK Activity: PCI v Isolated CABG

  9. Presentation Outline • Undisputed current facts • PCI improves access to revascularisation • Availability • Patients with co-morbidity • Patients with acute presentations • Acute coronary syndromes • Primary PCI for ST  MI • Cardiogenic shock

  10. Improved Cardiac Provision Favours PCI • Better primary prevention • Earlier investigation and treatment of CAD • Aggressive early approach to occlusion • Primary PCI for AMI • Early PCI for non-ST elevation ACS • Reduced incidence of • Advanced ‘surgical’ disease’

  11. Presentation Outline • Undisputed current facts • PCI improves access to revascularisation • PCI is cost saving

  12. SoS Trial - Total Costs at 1 Year Cost= £2,609 (95% CI: £1,769 to £3,314) £10,000 £9,000 £1,518 £8,000 Costs £7,000 Follow-up £6,000 £2,412 £5,000 Initial hosp £4,000 £3,000 £2,000 £3,884 £7,321 £1,000 £0 PCI CABG

  13. Presentation Outline • Undisputed current facts • PCI improves access to revascularisation • PCI is cost saving • PCI is popular with patients

  14. PCI - Appeal to Patients • Experience from consent attempts in RCTs • Shorter hospitalstay

  15. SoS Trial: Length of Stay - Index Procedure Median 3 days Median 10 days

  16. PCI - Appeal to Patients • Experience from consent attempts in RCTs • Shorter hospital stay • Reduced immediate procedural morbidity • Avoids GA, scars etc • Rapid rehabilitation • CABG option remains (short or long term)

  17. Presentation Outline • Undisputed current facts • PCI improves access to revascularisation • PCI is cost saving • PCI is popular with patients • PCI is improving at a rapid pace

  18. PCI Evolution • Rate of new product registration • Techniques and application • Adjunctive medication schedules • Imaging equipment • Devices / equipment • Stents and drug eluting stents • Improving clinical results

  19. Stenting and Emergency CABG

  20. Stenting and Restenosis Procedures

  21. Presentation Outline • Undisputed current facts • Historic trials favour CABG • Reduced repeat revascularisation

  22. SoS Trial: Repeat Revascularisation Hazard ratio 3.90 (2.58 to 5.91)

  23. SoS Trial: Death or Non-Fatal Q Wave MI Hazard ratio 0.95 (0.63 to 1.43)

  24. Mortality to 1 Year

  25. Presentation Outline • Undisputed current facts • Historic trials favour CABG • Reduced repeat revascularisation • Emerging clinical data - favours PCI

  26. PCI v CABG: The Current Picture • Non - MACCE adverse events • SoS data • Hospitalisation events after index revasc • Non - MACCE : Never reported • CABG 351 (0.7 per patient) • PCI 156 (0.3 per patient) • MACCE: PCI - superior safety and efficacy

  27. Latest Trials From TCT 2004 • ARTS 2 • Registry n = 607 MV revasc by DES • More diabetes than ARTS 1 (26% v 18%) • More 3 VD (54% v 28%) • More stents (3.7 [73mm] v 2.8 [48mm]) • 6 month freedom from MACCE • ARTS 2 - 93.6 % • ARTS 1: PCI - 84.7% CABG - 94.5%

  28. ARTS II - MACCE Free Survival

  29. ‘Armies can be resisted but not an idea whose time has come.’ Victor Hugo

More Related